These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease. Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A Digestion; 2021; 102(3):480-488. PubMed ID: 32062650 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388 [TBL] [Abstract][Full Text] [Related]
10. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Hojo M; Asaoka D; Takeda T; Shimada Y; Matsumoto K; Matsumoto K; Yatagai N; Akazawa Y; Ueda K; Ueyama H; Nagahara A Therap Adv Gastroenterol; 2020; 13():1756284820966247. PubMed ID: 33240391 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study. Pattarapuntakul T; Wong T; Wetwittayakhlang P; Netinatsunton N; Keeratichananont S; Kaewdech A; Jandee S; Chamroonkul N; Sripongpun P; Lakatos PL J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930134 [No Abstract] [Full Text] [Related]
12. Characteristics of proton pump inhibitor-resistant severe reflux esophagitis and efficacy of vonoprazan in elderly (older than 75 years) and non-elderly groups. Hoshino S; Momma E; Motomiya R; Tanabe T; Koeda M; Hoshikawa Y; Kawami N; Iwakiri K JGH Open; 2024 Jan; 8(1):e13023. PubMed ID: 38268954 [TBL] [Abstract][Full Text] [Related]
13. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Sue S; Maeda S Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058 [TBL] [Abstract][Full Text] [Related]
14. Incidence of Delayed Bleeding among Patients Continuing Antithrombotics during Gastric Endoscopic Submucosal Dissection. Kakushima N; Ono H; Takizawa K; Tanaka M; Kawata N; Yoshida M; Murai K; Yabuuchi Y; Kishida Y; Ito S; Imai K; Hotta K; Ishiwatari H; Matsubayashi H Intern Med; 2019; 58(19):2759-2766. PubMed ID: 31582592 [TBL] [Abstract][Full Text] [Related]
15. Role of Vonoprazan in Sugimoto M; Yamaoka Y Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158 [TBL] [Abstract][Full Text] [Related]
16. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044 [No Abstract] [Full Text] [Related]
17. Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases. Kubo K; Kimura N; Matsuda S; Tsuda M; Mabe K; Kato M Intern Med; 2020 Feb; 59(4):507-511. PubMed ID: 31611534 [TBL] [Abstract][Full Text] [Related]
18. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study. Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M Digestion; 2020; 101(5):608-614. PubMed ID: 31288235 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Shehryar M; Ahmad RU; Kareem HK; Khan L; Ashraf MF; Hassan A; Saeed S; Tareen HK; Nazir DA; Ashraf MA Ann Med Surg (Lond); 2022 Oct; 82():104760. PubMed ID: 36268393 [TBL] [Abstract][Full Text] [Related]